To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis-Reference-Cited by-同舟云学术

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis

Published:2015-09 Issue:3 Volume:73 Page:420-428.e1
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Ahn Christine S.,Dothard Emily H.,Garner Michael L.,Feldman Steven R.,Huang William W.

Publisher

Elsevier BV

Subject

Dermatology

Reference41 articles.

1. Trends in systemic psoriasis treatment therapies from 1993 through 2010;Shaw;J Drugs Dermatol,2014

2. FDA. What's new for biologics. http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WhatsNewforBiologics/default.htm. Accessed September 12, 2014.

3. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis;Motaparthi;J Am Acad Dermatol,2014

4. Japanese guidance for use of biologics for psoriasis (the 2013 version);Ohtsuki;J Dermatol,2013

5. European S3-guidelines on the systemic treatment of psoriasis vulgaris;Pathirana;J Eur Acad Dermatol Venereol,2009

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16

2. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy;Acta Dermato-Venereologica;2022-11-28

3. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»;Actas Dermo-Sifiliográficas;2022-06

4. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk;Actas Dermo-Sifiliográficas;2022-06

5. The seroconversion rate of QuantiFERON-TB gold in-tube test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies;Dermatologica Sinica;2022